What did Dr. Gupta say? It takes a big man to admit that he

New Post Public Reply Private Reply Replies (1) Message Board
bellsandwhistles
What did Dr. Gupta say? It takes a big man to admit that he was wrong, especially a distinguished man of the stature of Dr. Sanjay Gupta. This is his essay on what changed his mind about medical cannabis. Gupta once dismissed mmj, but is now a solid proponent based on the evidence and a historically  flawed classification. There are many revealing facts in this piece.

http://www.cnn.com/2013/08/08/health/gupta-ch...marijuana/
By Dr. Sanjay Gupta
08/08/2013

Over the last year, I have been working on a new documentary called "Weed." The title "Weed" may sound cavalier, but the content is not.

I traveled around the world to interview medical leaders, experts, growers and patients. I spoke candidly to them, asking tough questions. What I found was stunning.

Long before I began this project, I had steadily reviewed the scientific literature on medical marijuana from the United States and thought it was fairly unimpressive. Reading these papers five years ago, it was hard to make a case for medicinal marijuana. I even wrote about this in a TIME magazine article, back in 2009, titled "Why I would Vote No on Pot."

Well, I am here to apologize.

I apologize because I didn't look hard enough, until now. I didn't look far enough. I didn't review papers from smaller labs in other countries doing some remarkable research, and I was too dismissive of the loud chorus of legitimate patients whose symptoms improved on cannabis.

Instead, I lumped them with the high-visibility malingerers, just looking to get high. I mistakenly believed the Drug Enforcement Agency listed marijuana as a schedule 1 substance because of sound scientific proof. Surely, they must have quality reasoning as to why marijuana is in the category of the most dangerous drugs that have "no accepted medicinal use and a high potential for abuse."

They didn't have the science to support that claim, and I now know that when it comes to marijuana neither of those things are true. It doesn't have a high potential for abuse, and there are very legitimate medical applications. In fact, sometimes marijuana is the only thing that works. Take the case of Charlotte Figi, who I met in Colorado. She started having seizures soon after birth. By age 3, she was having 300 a week, despite being on seven different medications. Medical marijuana has calmed her brain, limiting her seizures to 2 or 3 per month.

I have seen more patients like Charlotte first hand, spent time with them and come to the realization that it is irresponsible not to provide the best care we can as a medical community, care that could involve marijuana.

We have been terribly and systematically misled for nearly 70 years in the United States, and I apologize for my own role in that.

I hope this article and upcoming documentary will help set the record straight.

On August 14, 1970, the Assistant Secretary of Health, Dr. Roger O. Egeberg wrote a letter recommending the plant, marijuana, be classified as a schedule 1 substance, and it has remained that way for nearly 45 years. My research started with a careful reading of that decades old letter. What I found was unsettling. Egeberg had carefully chosen his words:

"Since there is still a considerable void in our knowledge of the plant and effects of the active drug contained in it, our recommendation is that marijuana be retained within schedule 1 at least until the completion of certain studies now underway to resolve the issue."

Not because of sound science, but because of its absence, marijuana was classified as a schedule 1 substance. Again, the year was 1970. Egeberg mentions studies that are underway, but many were never completed. As my investigation continued, however, I realized Egeberg did in fact have important research already available to him, some of it from more than 25 years earlier.

High risk of abuse

In 1944, New York Mayor Fiorello LaGuardia commissioned research to be performed by the New York Academy of Science. Among their conclusions: they found marijuana did not lead to significant addiction in the medical sense of the word. They also did not find any evidence marijuana led to morphine, heroin or cocaine addiction.

We now know that while estimates vary, marijuana leads to dependence in around 9% to 10% of its adult users. By comparison, cocaine, a schedule 2 substance "with less abuse potential than schedule 1 drugs" hooks 20% of those who use it. Around 25% of heroin users become addicted.

The worst is tobacco, where the number is closer to 30% of smokers, many of whom go on to die because of their addiction.

There is clear evidence that in some people marijuana use can lead to withdrawal symptoms, including insomnia, anxiety and nausea. Even considering this, it is hard to make a case that it has a high potential for abuse. The physical symptoms of marijuana addiction are nothing like those of the other drugs I've mentioned. I have seen the withdrawal from alcohol, and it can be life threatening.

I do want to mention a concern that I think about as a father. Young, developing brains are likely more susceptible to harm from marijuana than adult brains. Some recent studies suggest that regular use in teenage years leads to a permanent decrease in IQ. Other research hints at a possible heightened risk of developing psychosis.

Much in the same way I wouldn't let my own children drink alcohol, I wouldn't permit marijuana until they are adults. If they are adamant about trying marijuana, I will urge them to wait until they're in their mid-20s when their brains are fully developed.

Medical benefit

While investigating, I realized something else quite important. Medical marijuana is not new, and the medical community has been writing about it for a long time. There were in fact hundreds of journal articles, mostly documenting the benefits. Most of those papers, however, were written between the years 1840 and 1930. The papers described the use of medical marijuana to treat "neuralgia, convulsive disorders, emaciation," among other things.

A search through the U.S. National Library of Medicine this past year pulled up nearly 20,000 more recent papers. But the majority were research into the harm of marijuana, such as "Bad trip due to anticholinergic effect of cannabis," or "Cannabis induced pancreatitits" and "Marijuana use and risk of lung cancer."

In my quick running of the numbers, I calculated about 6% of the current U.S. marijuana studies investigate the benefits of medical marijuana. The rest are designed to investigate harm. That imbalance paints a highly distorted picture.

The challenges of marijuana research

To do studies on marijuana in the United States today, you need two important things.

First of all, you need marijuana. And marijuana is illegal. You see the problem. Scientists can get research marijuana from a special farm in Mississippi, which is astonishingly located in the middle of the Ole Miss campus, but it is challenging. When I visited this year, there was no marijuana being grown.

The second thing you need is approval, and the scientists I interviewed kept reminding me how tedious that can be. While a cancer study may first be evaluated by the National Cancer Institute, or a pain study may go through the National Institute for Neurological Disorders, there is one more approval required for marijuana: NIDA, the National Institute on Drug Abuse. It is an organization that has a core mission of studying drug abuse, as opposed to benefit.

Stuck in the middle are the legitimate patients who depend on marijuana as a medicine, oftentimes as their only good option.

Keep in mind that up until 1943, marijuana was part of the United States drug pharmacopeia. One of the conditions for which it was prescribed was neuropathic pain. It is a miserable pain that's tough to treat. My own patients have described it as "lancinating, burning and a barrage of pins and needles." While marijuana has long been documented to be effective for this awful pain, the most common medications prescribed today come from the poppy plant, including morphine, oxycodone and dilaudid.

Here is the problem. Most of these medications don't work very well for this kind of pain, and tolerance is a real problem.

Most frightening to me is that someone dies in the United States every 19 minutes from a prescription drug overdose, mostly accidental. Every 19 minutes. It is a horrifying statistic. As much as I searched, I could not find a documented case of death from marijuana overdose.

It is perhaps no surprise then that 76% of physicians recently surveyed said they would approve the use of marijuana to help ease a woman's pain from breast cancer.

When marijuana became a schedule 1 substance, there was a request to fill a "void in our knowledge." In the United States, that has been challenging because of the infrastructure surrounding the study of an illegal substance, with a drug abuse organization at the heart of the approval process. And yet, despite the hurdles, we have made considerable progress that continues today.

Looking forward, I am especially intrigued by studies like those in Spain and Israel looking at the anti-cancer effects of marijuana and its components. I'm intrigued by the neuro-protective study by Lev Meschoulam in Israel, and research in Israel and the United States on whether the drug might help alleviate symptoms of PTSD. I promise to do my part to help, genuinely and honestly, fill the remaining void in our knowledge.

Citizens in 20 states and the District of Columbia have now voted to approve marijuana for medical applications, and more states will be making that choice soon. As for Dr. Roger Egeberg, who wrote that letter in 1970, he passed away 16 years ago.

I wonder what he would think if he were alive today.

http://www.cnn.com/2013/08/08/health/gupta-ch...marijuana/

SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCOM Secures $600M Deal to Boost NATO's Defense

Updated Category News Views 3

TCOM's Pivotal $600 Million Defense Contract How often do you hear about a deal north of $600 million that practically revamps a company's strategic future? That's precisely what's hitting the books at TCOM right now. They've scored a heavy-hitting Foreign Military Sales (FMS) contract to fortify NATO's eastern front with Poland. I'll tell you this—it’s one of the...

Continue Reading
Epson & The Photo Managers Highlight Memories in Sept.

Updated Category News Views 8

A Focus on Memory Preservation I remember a time when you kept memories in photo albums, dusty boxes in basements. Now, folks aim to digitize those moments before they're lost forever. With September here, Epson and The Photo Managers are telling us it's time for action. And hey, the campaign’s got a catchy name, 'One Photo, One Story.' Simple, yet it urges us all to...

Continue Reading
Zum Drivers Shine as New School Year Begins

Updated Category News Views 0

Opening the School Year with High Hopes Zum's crew of enthusiastic drivers hit the streets with a mission: kickstarting the new school year with a sense of excitement that feels fresh, even to a grizzled trader like me. These folks are doing more than just turning the ignition, they’re handling a vital cog in the education machine. From Fresno down to Rockford, you’ll...

Continue Reading
MacGregor's Bold Play: RoRo Tech for TT-Line's Ferries

Updated Category News Views 2

A Green Wave in the Baltic It looks like MacGregor's betting big on the future of maritime transport, and they're putting their chips down on TT-Line's next-gen battery-hybrid LNG ferries. With a contract fresh out of the oven, they've signed up to kit out these eco-warriors with a range of RoRo equipment. And let me tell you, this is no piddly order—by any stretch,...

Continue Reading
Supercharged Entertainment's Big Bet in Ohio's Polaris

Updated Category News Views 0

Fasten your seatbelts, folks—because there's a tinge of burnt rubber in the air at Columbus's Polaris Center. Supercharged Entertainment, the big guns in indoor karting, just kicked off construction at their brand-new venue, and it’s looking like a gearhead's paradise. A sprawling 16-acre parcel is set to become a haven for adrenaline junkies come Summer 2027. A Bold...

Continue Reading
Immunic Pushes Boundaries in MS with Vidofludimus

Updated Category News Views 1

Shaking Things Up in Multiple Sclerosis Therapy There's no telling how often the biotech sector tosses around the term 'game-changer,' but when Immunic's name comes up, more ears are perking up these days. The New York-based firm, waving the Nasdaq: IMUX flag, is lining up a virtual shindig come September 9, 2026, and for anyone invested in multiple sclerosis (MS) or...

Continue Reading
Axjo Group Expands in France with Eco-Tourets Buy

Updated Category News Views 6

Seizing the French Market: Axjo's Strategic Play Every now and then, you come across a company that's not just talking the talk but walking the green walk. Axjo Group's latest move—scooping up France's Eco-Tourets—puts them squarely in that league. It ain't just about expanding the footprint; it's about owning a piece of the future where sustainability isn't a...

Continue Reading
Tradr's Bold Venture: Anthropic ETFs Ahead of IPO

Updated Category News Views 2

Why Tradr Is Diving Into Anthropic's Hype There's a whiff of anticipation in the air as Anthropic gears up for its much-anticipated IPO, and Tradr isn't sitting on its hands here. They've just filed for two ETFs—one long, one short—ahead of the big day. We're talking about ANTT and ANTZ, betting on leveraged and inverse plays on whatever whirlwind Anthropic's stock...

Continue Reading
Early Education's Massive Impact: Key Skills for Success

Updated Category News Views 2

Unlocking Lifelong Success: The Early Advantage Ever look at a successful adult and wonder, "Where'd they get that spark?" According to HelloNation and child care expert Karen Ego, it all starts early. Think of early learning not just as prepping for school, but as the first blueprint for life's journey. It's the skills you pick up in those tender years that stick it out...

Continue Reading
Innventure Faces Class Action Over Alleged Deception

Updated Category News Views 3

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...

Continue Reading

Top 5 Most Recently Viewed Articles

Zealand Pharma A/S Updates Share Count and Voting Rights

Updated Category News Views 86

Zealand Pharma A/S, a key player in the biotech sector out of Copenhagen, confirmed back in early 2024 that it had a total of 71,023,871 shares outstanding. Each share carries a nominal value of DKK 1. This number isn’t just a footnote—it’s vital for any stakeholder keeping tabs on their stake or those considering diving into this space. The company’s compliance...

Continue Reading
CS Genetics Introduces Innovative SimpleCell™ Genomics Kits

Updated Category News Views 146

CS Genetics Launches SimpleCell™ for Enhanced Single-Cell Genomics Single-cell genomics has entered a new era with the exciting launch of SimpleCell™ 3' Gene Expression kits by CS Genetics, a pioneer in the field. This innovative platform simplifies the process of single-cell transcriptomics, making it more accessible and scalable than ever before. The Power of...

Continue Reading
LifeMD's Engagement at the Upcoming Growth Conference

Updated Category News Views 117

LifeMD's Participation in a Major Growth Conference LifeMD, Inc. (Nasdaq: LFMD), a prominent provider in the domain of virtual primary healthcare, has announced its upcoming participation in the Canaccord Genuity 45th Annual Growth Conference. This well-regarded event will take place from August 12 to 14, offering a dynamic platform for dialogue between investors and...

Continue Reading
Exploring Embedded Finance in India: Growth Forecasts to 2029

Updated Category News Views 306

The Future of Embedded Finance in India The embedded finance industry in India is on a remarkable growth trajectory. As we look ahead to the years leading up to 2029, projections indicate a compound annual growth rate (CAGR) of 37.8%, with revenue climbing from US$5.75 billion in 2024 to an impressive US$28.6 billion by the end of the forecast period. Transformative...

Continue Reading
Revolutionizing 3D Modeling: Fixstars Unveils CUMVS Software

Updated Category News Views 179

Revolutionizing 3D Modeling with CUMVS Software Fixstars Corporation, a leader in AI-driven software development, recently made waves with the open-source release of its groundbreaking software, CUMVS (cuda-multi-view-stereo), designed for rapid 3D model generation from 2D images. This innovative software allows users to create digital twins of real-world objects, marking...

Continue Reading